董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
John Snisarenko Director 60 5.00万美元 未持股 2023-06-29
Michael Kaseta Director 47 未披露 未持股 2023-06-29
Jason Werner Director 45 未披露 未持股 2023-06-29
Adam Morgan Director 44 未披露 未持股 2023-06-29
Erin Parsons Director 47 5.09万美元 未持股 2023-06-29
C. Daniel Myers Chair of the Board 69 8.50万美元 未持股 2023-06-29
Peter J. Pizzo, III Director 56 6.40万美元 未持股 2023-06-29
Richard S. Eiswirth President, Chief Executive Officer and Director 55 96.42万美元 未持股 2023-06-29

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Russell L. Skibsted Senior Vice President and Chief Financial Officer 63 未披露 未持股 2023-06-29
Richard S. Eiswirth President, Chief Executive Officer and Director 55 96.42万美元 未持股 2023-06-29
David Holland Chief Marketing Officer, Senior Vice President Corporate Communications and Managed Markets 59 54.17万美元 未持股 2023-06-29
Philip Ashman Chief Operating Officer and Senior Vice President Commercial Operations Europe 58 60.97万美元 未持股 2023-06-29

董事简历

中英对照 |  中文 |  英文
John Snisarenko

John Snisarenko自2019年9月起担任我们的首席商务官。Snisarenko先生最近于2017年6月至2019年9月担任Takeda Pharmaceuticals先前Shire眼科业务部的集团Vice President。在加入Shire之前,斯尼萨连科曾于2007年12月至2017年5月担任Genentech眼科业务部门的Vice President。2006年4月至2007年12月,Snisarenko先生是Novadaq Technologies眼科业务的Vice President,1996年6月至2006年4月,他是Novartis Pharmaceuticals Canada眼科业务的Vice President。Snisarenko先生自2019年7月起担任AlimeraSciences,Inc.(NASDAQ:ALIM)董事会成员。Snisarenko先生获得工商管理学士学位。McGill University生物化学硕士学位和工商管理硕士学位。


John Snisarenko,has been a member of the Board since July 2019. Mr. Snisarenko served as Chief Commercial Officer of Oyster Point Pharma, Inc. from September 2019 until his retirement in July 2022. He previously served as Group Vice President and Head of the Ophthalmics Franchise of Shire (now Takeda) from June 2017 until June 2019. Mr. Snisarenko led a large, multidisciplinary team in Shire's launch of Xiidra and also served as a member of Shire's Commercial Leadership Team. In 2019, Mr. Snisarenko was a key member in the divestiture of the Ophthalmology Franchise to Novartis Pharma. Prior to joining Shire, Mr. Snisarenko was the Franchise Head responsible for the commercial activities within Genentech's Ophthalmology (Lucentis) and Rheumatology (Rituxan, Actemra) franchises for 10 years. A 30 plus year veteran of the pharmaceutical/biotech industry, Mr. Snisarenko also held various positions of increasing responsibility at CIBA Vision / Novartis Pharma. In his last nine years, he served as Vice President and Business Unit Head for Novartis Ophthalmics, holding general management responsibilities for the Canadian business. Mr. Snisarenko has held numerous advisory board positions and was a board member for the Foundation Fighting Blindness in Canada. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.
John Snisarenko自2019年9月起担任我们的首席商务官。Snisarenko先生最近于2017年6月至2019年9月担任Takeda Pharmaceuticals先前Shire眼科业务部的集团Vice President。在加入Shire之前,斯尼萨连科曾于2007年12月至2017年5月担任Genentech眼科业务部门的Vice President。2006年4月至2007年12月,Snisarenko先生是Novadaq Technologies眼科业务的Vice President,1996年6月至2006年4月,他是Novartis Pharmaceuticals Canada眼科业务的Vice President。Snisarenko先生自2019年7月起担任AlimeraSciences,Inc.(NASDAQ:ALIM)董事会成员。Snisarenko先生获得工商管理学士学位。McGill University生物化学硕士学位和工商管理硕士学位。
John Snisarenko,has been a member of the Board since July 2019. Mr. Snisarenko served as Chief Commercial Officer of Oyster Point Pharma, Inc. from September 2019 until his retirement in July 2022. He previously served as Group Vice President and Head of the Ophthalmics Franchise of Shire (now Takeda) from June 2017 until June 2019. Mr. Snisarenko led a large, multidisciplinary team in Shire's launch of Xiidra and also served as a member of Shire's Commercial Leadership Team. In 2019, Mr. Snisarenko was a key member in the divestiture of the Ophthalmology Franchise to Novartis Pharma. Prior to joining Shire, Mr. Snisarenko was the Franchise Head responsible for the commercial activities within Genentech's Ophthalmology (Lucentis) and Rheumatology (Rituxan, Actemra) franchises for 10 years. A 30 plus year veteran of the pharmaceutical/biotech industry, Mr. Snisarenko also held various positions of increasing responsibility at CIBA Vision / Novartis Pharma. In his last nine years, he served as Vice President and Business Unit Head for Novartis Ophthalmics, holding general management responsibilities for the Canadian business. Mr. Snisarenko has held numerous advisory board positions and was a board member for the Foundation Fighting Blindness in Canada. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.
Michael Kaseta

Michael Kaseta,自2023年3月起担任董事会成员。Kaseta先生自2020年11月起担任Liquidia Corporation首席财务官。Kaseta先生于2019年1月至2020年11月担任Aerami Therapeutics,Inc.的首席财务官,该公司是一家私营生物技术公司,专注于开发治疗严重呼吸系统疾病(包括肺动脉高压)的改良疗法,并于2018年3月开始担任前专业制药公司(“Aralez”)Aralez制药公司的首席财务官。Aralez于2018年8月申请破产保护,Kaseta先生一直担任Aralez的首席财务官,直到2019年1月离职。Kaseta先生曾于2017年11月至2018年3月担任Aralez的财务主管兼临时首席财务官,并于2016年9月至2017年11月担任公司财务总监。在加入Aralez之前,Kaseta先生曾在专注于人类健康的全球生物制药公司赛诺菲 S.A.担任多个职位,包括2015年4月至2016年9月担任赛诺菲北美全球服务部首席财务官。Kaseta先生曾于2013年1月至2015年4月担任赛诺菲北美制药控制副总裁,于2007年3月至2013年12月担任赛诺菲财务共享服务副总裁,并于2005年至2007年担任技术会计总监。Kaseta先生拥有詹姆斯麦迪逊大学会计学学士学位,是新泽西州的注册会计师(非在职)。


Michael Kaseta,has been a member of the Board since March 2023. Mr. Kaseta has served as Chief Financial Officer of Liquidia Corporation since November 2020. Mr. Kaseta served as Chief Financial Officer of Aerami Therapeutics, Inc., a privately held biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as Chief Financial Officer of Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company ("Aralez"), beginning in March 2018. Aralez filed for bankruptcy protection in August 2018, and Mr. Kaseta remained Chief Financial Officer of Aralez until his departure in January 2019. Mr. Kaseta previously served as Head of Finance and Interim Chief Financial Officer of Aralez from November 2017 until March 2018 and Corporate Controller from September 2016 until November 2017. Prior to joining Aralez, Mr. Kaseta held various positions at Sanofi S.A., a global biopharmaceutical company focused on human health, including most recently Chief Financial Officer Sanofi North America, Global Services, from April 2015 through September 2016. Mr. Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January 2013 through April 2015, Vice President, Sanofi Financial Shared Services from March 2007 through December 2013 and Director of Technical Accounting from 2005 to 2007. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.
Michael Kaseta,自2023年3月起担任董事会成员。Kaseta先生自2020年11月起担任Liquidia Corporation首席财务官。Kaseta先生于2019年1月至2020年11月担任Aerami Therapeutics,Inc.的首席财务官,该公司是一家私营生物技术公司,专注于开发治疗严重呼吸系统疾病(包括肺动脉高压)的改良疗法,并于2018年3月开始担任前专业制药公司(“Aralez”)Aralez制药公司的首席财务官。Aralez于2018年8月申请破产保护,Kaseta先生一直担任Aralez的首席财务官,直到2019年1月离职。Kaseta先生曾于2017年11月至2018年3月担任Aralez的财务主管兼临时首席财务官,并于2016年9月至2017年11月担任公司财务总监。在加入Aralez之前,Kaseta先生曾在专注于人类健康的全球生物制药公司赛诺菲 S.A.担任多个职位,包括2015年4月至2016年9月担任赛诺菲北美全球服务部首席财务官。Kaseta先生曾于2013年1月至2015年4月担任赛诺菲北美制药控制副总裁,于2007年3月至2013年12月担任赛诺菲财务共享服务副总裁,并于2005年至2007年担任技术会计总监。Kaseta先生拥有詹姆斯麦迪逊大学会计学学士学位,是新泽西州的注册会计师(非在职)。
Michael Kaseta,has been a member of the Board since March 2023. Mr. Kaseta has served as Chief Financial Officer of Liquidia Corporation since November 2020. Mr. Kaseta served as Chief Financial Officer of Aerami Therapeutics, Inc., a privately held biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as Chief Financial Officer of Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company ("Aralez"), beginning in March 2018. Aralez filed for bankruptcy protection in August 2018, and Mr. Kaseta remained Chief Financial Officer of Aralez until his departure in January 2019. Mr. Kaseta previously served as Head of Finance and Interim Chief Financial Officer of Aralez from November 2017 until March 2018 and Corporate Controller from September 2016 until November 2017. Prior to joining Aralez, Mr. Kaseta held various positions at Sanofi S.A., a global biopharmaceutical company focused on human health, including most recently Chief Financial Officer Sanofi North America, Global Services, from April 2015 through September 2016. Mr. Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January 2013 through April 2015, Vice President, Sanofi Financial Shared Services from March 2007 through December 2013 and Director of Technical Accounting from 2005 to 2007. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.
Jason Werner

Jason Werner,自2023年5月起担任董事会成员。Werner先生自2021年5月起担任临床前阶段生物技术公司Sightstream Biotherapeutics,Inc.的首席执行官和董事。沃纳先生曾担任Eyevance Pharmaceuticals Holdings Inc.的联合创始人和首席运营官,Eyevance Pharmaceuticals Holdings Inc.是一家眼科外用产品开发商,从2017年9月至2020年9月被参天制药有限公司收购。在此之前,Werner先生曾在Sun Pharmaceutical Industries Ltd.和激励制药担任商业发展和全球战略方面的多个职位,并在辉瑞公司担任一线销售工作。Werner先生在新罕布什尔大学获得了工商管理理学学士学位。


Jason Werner,has been a member of the Board since May 2023. Mr. Werner currently serves as Chief Executive Officer and a director of Sightstream Biotherapeutics, Inc., a preclinical stage biotechnology company, since May 2021. Mr. Werner previously served as Co-Founder and Chief Operating Officer of Eyevance Pharmaceuticals Holdings Inc., a developer of topical ophthalmic products, from September 2017 through its acquisition by Santen Pharmaceutical Co., Ltd. in September 2020. Prior to that, Mr. Werner held various positions in Commercial Development and Global Strategy at Sun Pharmaceutical Industries Ltd. and Inspire Pharmaceuticals, Inc., as well as front line sales for Pfizer Inc. Mr. Werner earned his Bachelor of Science in Business Administration from the University of New Hampshire.
Jason Werner,自2023年5月起担任董事会成员。Werner先生自2021年5月起担任临床前阶段生物技术公司Sightstream Biotherapeutics,Inc.的首席执行官和董事。沃纳先生曾担任Eyevance Pharmaceuticals Holdings Inc.的联合创始人和首席运营官,Eyevance Pharmaceuticals Holdings Inc.是一家眼科外用产品开发商,从2017年9月至2020年9月被参天制药有限公司收购。在此之前,Werner先生曾在Sun Pharmaceutical Industries Ltd.和激励制药担任商业发展和全球战略方面的多个职位,并在辉瑞公司担任一线销售工作。Werner先生在新罕布什尔大学获得了工商管理理学学士学位。
Jason Werner,has been a member of the Board since May 2023. Mr. Werner currently serves as Chief Executive Officer and a director of Sightstream Biotherapeutics, Inc., a preclinical stage biotechnology company, since May 2021. Mr. Werner previously served as Co-Founder and Chief Operating Officer of Eyevance Pharmaceuticals Holdings Inc., a developer of topical ophthalmic products, from September 2017 through its acquisition by Santen Pharmaceutical Co., Ltd. in September 2020. Prior to that, Mr. Werner held various positions in Commercial Development and Global Strategy at Sun Pharmaceutical Industries Ltd. and Inspire Pharmaceuticals, Inc., as well as front line sales for Pfizer Inc. Mr. Werner earned his Bachelor of Science in Business Administration from the University of New Hampshire.
Adam Morgan

Adam Morgan,自2023年3月起担任董事会成员。自2020年7月以来,摩根一直担任Velan Capital Investment Management LP的首席投资官,该公司是一家专注于医疗保健的投资公司,总部位于乔治亚州阿尔法利塔。摩根先生目前还担任Heron Therapeutics, Inc.(纳斯达克股票代码:HRTX)的董事会成员,该公司是一家上市生物技术公司,专注于提高急性和肿瘤患者的护理标准,自2023年2月起,他还担任该公司董事会主席和公司提名和公司治理委员会成员,以及健康展望公司,这是一家位于纽约州的预测性医疗保健技术和服务的私人开发商,自2023年1月起,他还担任公司审计委员会主席。此前,摩根曾于2018年2月至2020年6月担任Broadfin Capital,LLC高级分析师,这是一家专注于医疗保健的投资公司,总部位于纽约州纽约市,负责生物技术和制药行业。在此之前,摩根曾在Iguana Healthcare Partners LLC担任高级分析师,该公司是一家专注于医疗保健的投资公司,总部位于纽约州纽约市,2015年至2018年1月,他在该公司负责医疗器械和专业制药业务。摩根还曾在Pura Vida Investments,LLC担任分析师,这是一家专注于医疗保健的投资公司,2014年至2015年,他在该公司负责全球医疗器械业务。在其职业生涯的早期,摩根先生于2014年1月至2014年6月在金融服务公司高宏集团公司(Cowen Inc.的子公司)担任医疗用品和设备团队的研究助理。摩根先生在明尼苏达大学获得化学理学士学位,在明尼苏达大学卡尔森管理学院获得MBA学位。


Adam Morgan,has been a member of the Board since March 2023. Mr. Morgan has served as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia, since July 2020. Mr. Morgan also currently serves on the board of directors of Heron Therapeutics, Inc. (NASDAQ: HRTX), a publicly-listed biotechnology company focused on advancing the standard of care for acute and oncology patients, where he also serves as Chairman of the board of directors and as a member of the company's nominating and corporate governance committee, since February 2023, and Health Outlook Corporation, a privately held developer of predictive healthcare technology and service based in New York, New York, where he also serves as chair of the company's audit committee, since January 2023. Previously, Mr. Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and Pharmaceutical sectors, from February 2018 to June 2020. Prior to that, Mr. Morgan served as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices and Specialty Pharmaceuticals, from 2015 to January 2018. Mr. Morgan also served as an Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career, Mr. Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm's Medical Supplies and Devices team, from January 2014 to June 2014. Mr. Morgan earned his Bachelor of Science in Chemistry from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota.
Adam Morgan,自2023年3月起担任董事会成员。自2020年7月以来,摩根一直担任Velan Capital Investment Management LP的首席投资官,该公司是一家专注于医疗保健的投资公司,总部位于乔治亚州阿尔法利塔。摩根先生目前还担任Heron Therapeutics, Inc.(纳斯达克股票代码:HRTX)的董事会成员,该公司是一家上市生物技术公司,专注于提高急性和肿瘤患者的护理标准,自2023年2月起,他还担任该公司董事会主席和公司提名和公司治理委员会成员,以及健康展望公司,这是一家位于纽约州的预测性医疗保健技术和服务的私人开发商,自2023年1月起,他还担任公司审计委员会主席。此前,摩根曾于2018年2月至2020年6月担任Broadfin Capital,LLC高级分析师,这是一家专注于医疗保健的投资公司,总部位于纽约州纽约市,负责生物技术和制药行业。在此之前,摩根曾在Iguana Healthcare Partners LLC担任高级分析师,该公司是一家专注于医疗保健的投资公司,总部位于纽约州纽约市,2015年至2018年1月,他在该公司负责医疗器械和专业制药业务。摩根还曾在Pura Vida Investments,LLC担任分析师,这是一家专注于医疗保健的投资公司,2014年至2015年,他在该公司负责全球医疗器械业务。在其职业生涯的早期,摩根先生于2014年1月至2014年6月在金融服务公司高宏集团公司(Cowen Inc.的子公司)担任医疗用品和设备团队的研究助理。摩根先生在明尼苏达大学获得化学理学士学位,在明尼苏达大学卡尔森管理学院获得MBA学位。
Adam Morgan,has been a member of the Board since March 2023. Mr. Morgan has served as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia, since July 2020. Mr. Morgan also currently serves on the board of directors of Heron Therapeutics, Inc. (NASDAQ: HRTX), a publicly-listed biotechnology company focused on advancing the standard of care for acute and oncology patients, where he also serves as Chairman of the board of directors and as a member of the company's nominating and corporate governance committee, since February 2023, and Health Outlook Corporation, a privately held developer of predictive healthcare technology and service based in New York, New York, where he also serves as chair of the company's audit committee, since January 2023. Previously, Mr. Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and Pharmaceutical sectors, from February 2018 to June 2020. Prior to that, Mr. Morgan served as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices and Specialty Pharmaceuticals, from 2015 to January 2018. Mr. Morgan also served as an Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career, Mr. Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm's Medical Supplies and Devices team, from January 2014 to June 2014. Mr. Morgan earned his Bachelor of Science in Chemistry from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota.
Erin Parsons

Erin Parsons,自2021年11月起担任董事会成员。自2010年成立以来,Parsons女士一直担任Parsons医疗通讯公司的创始人和总裁,该公司为眼科领域的大小公司提供科学和战略咨询。Parsons女士自2022年2月起担任Kiora Pharmaceuticals, Inc.董事会成员,该公司是一家眼科专业制药公司,开发治疗不同类型眼病的疗法。Parsons女士还参与了眼部护理领域的各种协会,包括眼科世界领袖、眼科创新峰会(她在会上主持了关于KOL倡导的大师班)和荷兰视力恢复基金会。Parsons女士在维克森林大学获得生物学学士学位。


Erin Parsons,has been a member of the Board since November 2021. Ms. Parsons has served as Founder and President of Parsons Medical Communications, LLC, an agency providing scientific and strategic consulting to small and large companies in the ophthalmic space, since its founding in 2010. Ms. Parsons has served as a member of the board of directors of Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases, since February 2022. Ms. Parsons is also involved with various associations in the eyecare space including Ophthalmic World Leaders, the Ophthalmology Innovation Summit (where she led a Masterclass on KOL Advocacy), and The Holland Foundation for Sight Restoration. Ms. Parsons received a Bachelor of Science in Biology from Wake Forest University.
Erin Parsons,自2021年11月起担任董事会成员。自2010年成立以来,Parsons女士一直担任Parsons医疗通讯公司的创始人和总裁,该公司为眼科领域的大小公司提供科学和战略咨询。Parsons女士自2022年2月起担任Kiora Pharmaceuticals, Inc.董事会成员,该公司是一家眼科专业制药公司,开发治疗不同类型眼病的疗法。Parsons女士还参与了眼部护理领域的各种协会,包括眼科世界领袖、眼科创新峰会(她在会上主持了关于KOL倡导的大师班)和荷兰视力恢复基金会。Parsons女士在维克森林大学获得生物学学士学位。
Erin Parsons,has been a member of the Board since November 2021. Ms. Parsons has served as Founder and President of Parsons Medical Communications, LLC, an agency providing scientific and strategic consulting to small and large companies in the ophthalmic space, since its founding in 2010. Ms. Parsons has served as a member of the board of directors of Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases, since February 2022. Ms. Parsons is also involved with various associations in the eyecare space including Ophthalmic World Leaders, the Ophthalmology Innovation Summit (where she led a Masterclass on KOL Advocacy), and The Holland Foundation for Sight Restoration. Ms. Parsons received a Bachelor of Science in Biology from Wake Forest University.
C. Daniel Myers

C. Daniel Myers,他是公司的共同创办人之一,公司于2003年成立以来他一直担任公司行政总裁及董事。在创办公司前,他为诺华眼药公司和视康公司的第一批员工眼药,并从1991年至1997年担任销售和营销的副总裁,从1997至2003年担任总裁。他持有佐治亚理工学院工业管理学士学位。


C. Daniel Myers,is one of Alimera Sciences, Inc. co-founders and has served as a director since the founding of the Company in 2003 and as chair of Alimera Sciences, Inc. nominating and corporate governance committee since March 2023. He served as Alimera Sciences, Inc. Chief Executive Officer from 2003 until January 2019, when he retired from that role, was elected Chair of the Board. Mr. Myers served as a consultant to Alimera Sciences, Inc. upon his retirement until December 2021. Before co-founding the Company, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc. from 2009 to 2012. From April 2020 until April 2022, Mr. Myers served as the CEO of MediPrint Ophthalmics, Inc. (formerly Leo Lens Technology Co., Inc.), a privately held San Diego, California-based clinical stage eye care pharmaceutical company. Mr. Myers has served on the board of directors of Kala Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye, since October 2021. Mr. Myers holds a Bachelor of Science in Industrial Management from the Georgia Institute of Technology.
C. Daniel Myers,他是公司的共同创办人之一,公司于2003年成立以来他一直担任公司行政总裁及董事。在创办公司前,他为诺华眼药公司和视康公司的第一批员工眼药,并从1991年至1997年担任销售和营销的副总裁,从1997至2003年担任总裁。他持有佐治亚理工学院工业管理学士学位。
C. Daniel Myers,is one of Alimera Sciences, Inc. co-founders and has served as a director since the founding of the Company in 2003 and as chair of Alimera Sciences, Inc. nominating and corporate governance committee since March 2023. He served as Alimera Sciences, Inc. Chief Executive Officer from 2003 until January 2019, when he retired from that role, was elected Chair of the Board. Mr. Myers served as a consultant to Alimera Sciences, Inc. upon his retirement until December 2021. Before co-founding the Company, Mr. Myers was an initial employee of Novartis Ophthalmics (formerly CIBA Vision Ophthalmics) and served as its Vice President of Sales and Marketing from 1991 to 1997 and as President from 1997 to 2003. In addition, Mr. Myers served on the board of directors of Ocular Therapeutix, Inc. from 2009 to 2012. From April 2020 until April 2022, Mr. Myers served as the CEO of MediPrint Ophthalmics, Inc. (formerly Leo Lens Technology Co., Inc.), a privately held San Diego, California-based clinical stage eye care pharmaceutical company. Mr. Myers has served on the board of directors of Kala Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye, since October 2021. Mr. Myers holds a Bachelor of Science in Industrial Management from the Georgia Institute of Technology.
Peter J. Pizzo, III

Peter J. Pizzo, III,自2010年4月他一直是公司董事会的成员。自2005年该公司成立以来,他曾担任Carticept医药公司(私人骨科医疗设备的公司)的财务副总裁兼首席财务官,该公司是他与人合作创办。从2002年直到2005年他担任比邻治疗公司(为固体癌症肿瘤治疗开发和销售当地的辐射传递系统的私人医疗器械公司)的财务副总裁兼首席财务官。从1996年至2001年他曾任职于Serologicals公司(一家公开上市的生物制品全球供应商),最终担任财务副总裁和首席财务官。从1995年到1996年,他担任ValueMark医疗系统公司(一家精神病医院的私人持有业主运营商)行政副总裁和财务主管。从1992年到1995年他曾担任霍尔马克医疗保健公司(一家公开上市的医院管理公司)的多个高级财务职位。他持有华盛顿和李大学的商务专业科学素养学士学位。


Peter J. Pizzo, III,has been a member of the Board since April 2010. Since August 2022, Mr. Pizzo has served as Chief Financial Officer of Intrinsic Therapeutics, Inc., a privately held medical device company that has developed and is commercializing a product to prevent reherniation and reoperation following lumbar discectomy surgery. From October 2019 until June 2022, Mr. Pizzo served as Chief Financial Officer for ControlRad, Inc, a privately held medical technology company focused on reducing unnecessary radiation exposure during fluoroscopically guided procedures. From October 2018 until September 2019, Mr. Pizzo provided financial consulting services to medical device companies. From 2005 until October 2018, Mr. Pizzo served as Chief Financial Officer of Carticept Medical, Inc., a private medical device company, and from its spinout from Carticept in December 2011 until its sale in October 2018, as Chief Financial Officer of Cartiva, Inc., a privately held orthopedic medical device company. From 2002 until its sale in 2005, Mr. Pizzo served as Chief Financial Officer of Proxima Therapeutics, Inc., a privately held medical device company. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded global provider of biological products to life science companies, ultimately serving as Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals. From 1992 until its sale in 1995, Mr. Pizzo served in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University.
Peter J. Pizzo, III,自2010年4月他一直是公司董事会的成员。自2005年该公司成立以来,他曾担任Carticept医药公司(私人骨科医疗设备的公司)的财务副总裁兼首席财务官,该公司是他与人合作创办。从2002年直到2005年他担任比邻治疗公司(为固体癌症肿瘤治疗开发和销售当地的辐射传递系统的私人医疗器械公司)的财务副总裁兼首席财务官。从1996年至2001年他曾任职于Serologicals公司(一家公开上市的生物制品全球供应商),最终担任财务副总裁和首席财务官。从1995年到1996年,他担任ValueMark医疗系统公司(一家精神病医院的私人持有业主运营商)行政副总裁和财务主管。从1992年到1995年他曾担任霍尔马克医疗保健公司(一家公开上市的医院管理公司)的多个高级财务职位。他持有华盛顿和李大学的商务专业科学素养学士学位。
Peter J. Pizzo, III,has been a member of the Board since April 2010. Since August 2022, Mr. Pizzo has served as Chief Financial Officer of Intrinsic Therapeutics, Inc., a privately held medical device company that has developed and is commercializing a product to prevent reherniation and reoperation following lumbar discectomy surgery. From October 2019 until June 2022, Mr. Pizzo served as Chief Financial Officer for ControlRad, Inc, a privately held medical technology company focused on reducing unnecessary radiation exposure during fluoroscopically guided procedures. From October 2018 until September 2019, Mr. Pizzo provided financial consulting services to medical device companies. From 2005 until October 2018, Mr. Pizzo served as Chief Financial Officer of Carticept Medical, Inc., a private medical device company, and from its spinout from Carticept in December 2011 until its sale in October 2018, as Chief Financial Officer of Cartiva, Inc., a privately held orthopedic medical device company. From 2002 until its sale in 2005, Mr. Pizzo served as Chief Financial Officer of Proxima Therapeutics, Inc., a privately held medical device company. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded global provider of biological products to life science companies, ultimately serving as Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals. From 1992 until its sale in 1995, Mr. Pizzo served in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University.
Richard S. Eiswirth

Richard S. Eiswirth,自2005年10月起,他担任公司首席财务官,自2010年8月担任首席营运官。从2003年至2005年 他担任创始品牌点火集团的合作伙伴,从事消费产品的收购活动。从2002年到2005 年他担任黑河控股公司(他于2002年成立的财务顾问公司)的总裁。他担任Netzee公司(为社区银行提供网上银行解决方案的供应商)的财务总监和高级执行副总裁从1999至2002年。1991至1999年,他在安达信担任了多种职位,在那里他开始了他的职业生涯。他曾任董事长琼斯纯碱公司(西雅图,华盛顿的饮料公司)的董事长,审核委员会主席及薪酬委员会成员各种职位有限公司,和彩色成像公司(一家格鲁吉亚的诺克罗斯的打印机和复印机原材料的生产商)的董事及审核委员会主席。 他曾是格鲁吉亚的执业会计师。 他持有维克森林大学的会计学士学位。


Richard S. Eiswirth,has served as Alimera Sciences, Inc. Chief Executive Officer and a member of the Board since January 2019. Mr. Eiswirth had previously served as Alimera Sciences, Inc. President and Chief Financial Officer since January 2016. Before that, he served as Alimera Sciences, Inc. Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as Alimera Sciences, Inc. Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks, from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chair, audit committee chair and member of the compensation committee of Jones Soda Co., a Seattle, Washington-based beverage company, and as director and audit committee chair of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a CPA in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.
Richard S. Eiswirth,自2005年10月起,他担任公司首席财务官,自2010年8月担任首席营运官。从2003年至2005年 他担任创始品牌点火集团的合作伙伴,从事消费产品的收购活动。从2002年到2005 年他担任黑河控股公司(他于2002年成立的财务顾问公司)的总裁。他担任Netzee公司(为社区银行提供网上银行解决方案的供应商)的财务总监和高级执行副总裁从1999至2002年。1991至1999年,他在安达信担任了多种职位,在那里他开始了他的职业生涯。他曾任董事长琼斯纯碱公司(西雅图,华盛顿的饮料公司)的董事长,审核委员会主席及薪酬委员会成员各种职位有限公司,和彩色成像公司(一家格鲁吉亚的诺克罗斯的打印机和复印机原材料的生产商)的董事及审核委员会主席。 他曾是格鲁吉亚的执业会计师。 他持有维克森林大学的会计学士学位。
Richard S. Eiswirth,has served as Alimera Sciences, Inc. Chief Executive Officer and a member of the Board since January 2019. Mr. Eiswirth had previously served as Alimera Sciences, Inc. President and Chief Financial Officer since January 2016. Before that, he served as Alimera Sciences, Inc. Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as Alimera Sciences, Inc. Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks, from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chair, audit committee chair and member of the compensation committee of Jones Soda Co., a Seattle, Washington-based beverage company, and as director and audit committee chair of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a CPA in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.

高管简历

中英对照 |  中文 |  英文
Russell L. Skibsted

Russell L. Skibsted,自2023年1月起担任Alimera Sciences, Inc.高级副总裁兼首席财务官。在被任命为Alimera Sciences, Inc.首席财务官和高级副总裁之前,Skibsted先生曾于2020年9月至2022年11月担任Rockwell Medical, Inc.的首席财务官和首席商务官。TERM3是一家商业医疗保健公司,专注于为患有血液疾病和肾脏相关疾病的患者提供维持生命的产品。此前,Skibsted先生曾于2017年7月至2020年5月担任AgeX Therapeutics公司的首席财务官,该公司是一家上市生物技术公司,专注于针对衰老疾病的细胞疗法,是从BioTime公司(现为Lineage Cell Therapeutics, Inc.)剥离出来的。在此之前,他曾于2015年11月至2019年1月担任BioTime,Inc.的首席财务官,BioTime是一家处于临床阶段的生物技术公司,在此期间,他不时担任BioTime几家上市和私营子公司的首席财务官,包括AgeX Therapeutics、OncoCyte Corporation,后者是一家上市的新型非侵入性癌症早期检测测试开发商,曾于2015年11月至2017年11月担任BioTime,Inc.的子公司,海星生物治疗公司,从2016年3月到2016年11月,这家生物技术公司开创了再生医学领域的先河,在脊髓损伤和肿瘤免疫治疗方面拥有临床项目,曾是BioTime公司的子公司。斯基布斯特德拥有克莱蒙特麦肯纳学院的经济学学士学位和斯坦福大学商学院的MBA学位。


Russell L. Skibsted,has served as Alimera Sciences, Inc. Senior Vice President and Chief Financial Officer since January 2023. Prior to his appointment as Alimera Sciences, Inc. Chief Financial Officer and Senior Vice President, Mr. Skibsted served as Chief Financial Officer and Chief Business Officer of Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, from September 2020 until November 2022. Previously, Mr. Skibsted served as Chief Financial Officer of AgeX Therapeutics, Inc., a publicly-traded biotechnology company focused on cell therapy targeting the diseases of aging that was spun out of BioTime, Inc. (currently Lineage Cell Therapeutics, Inc.), from July 2017 to May 2020. Prior to that, he served as Chief Financial Officer of BioTime, Inc., a clinical-stage biotechnology company, from November 2015 to January 2019, where he simultaneously, from time to time, performed the role of Chief Financial Officer for several of BioTime's public and private subsidiaries, including AgeX Therapeutics, OncoCyte Corporation, a publicly-traded developer of novel, non-invasive tests for the early detection of cancer and a former subsidiary of BioTime, Inc., from November 2015 until November 2017, and Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine with clinical programs in spinal cord injury and oncology immunotherapy and a former subsidiary of BioTime, Inc., from March 2016 until November 2016. Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.
Russell L. Skibsted,自2023年1月起担任Alimera Sciences, Inc.高级副总裁兼首席财务官。在被任命为Alimera Sciences, Inc.首席财务官和高级副总裁之前,Skibsted先生曾于2020年9月至2022年11月担任Rockwell Medical, Inc.的首席财务官和首席商务官。TERM3是一家商业医疗保健公司,专注于为患有血液疾病和肾脏相关疾病的患者提供维持生命的产品。此前,Skibsted先生曾于2017年7月至2020年5月担任AgeX Therapeutics公司的首席财务官,该公司是一家上市生物技术公司,专注于针对衰老疾病的细胞疗法,是从BioTime公司(现为Lineage Cell Therapeutics, Inc.)剥离出来的。在此之前,他曾于2015年11月至2019年1月担任BioTime,Inc.的首席财务官,BioTime是一家处于临床阶段的生物技术公司,在此期间,他不时担任BioTime几家上市和私营子公司的首席财务官,包括AgeX Therapeutics、OncoCyte Corporation,后者是一家上市的新型非侵入性癌症早期检测测试开发商,曾于2015年11月至2017年11月担任BioTime,Inc.的子公司,海星生物治疗公司,从2016年3月到2016年11月,这家生物技术公司开创了再生医学领域的先河,在脊髓损伤和肿瘤免疫治疗方面拥有临床项目,曾是BioTime公司的子公司。斯基布斯特德拥有克莱蒙特麦肯纳学院的经济学学士学位和斯坦福大学商学院的MBA学位。
Russell L. Skibsted,has served as Alimera Sciences, Inc. Senior Vice President and Chief Financial Officer since January 2023. Prior to his appointment as Alimera Sciences, Inc. Chief Financial Officer and Senior Vice President, Mr. Skibsted served as Chief Financial Officer and Chief Business Officer of Rockwell Medical, Inc., a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, from September 2020 until November 2022. Previously, Mr. Skibsted served as Chief Financial Officer of AgeX Therapeutics, Inc., a publicly-traded biotechnology company focused on cell therapy targeting the diseases of aging that was spun out of BioTime, Inc. (currently Lineage Cell Therapeutics, Inc.), from July 2017 to May 2020. Prior to that, he served as Chief Financial Officer of BioTime, Inc., a clinical-stage biotechnology company, from November 2015 to January 2019, where he simultaneously, from time to time, performed the role of Chief Financial Officer for several of BioTime's public and private subsidiaries, including AgeX Therapeutics, OncoCyte Corporation, a publicly-traded developer of novel, non-invasive tests for the early detection of cancer and a former subsidiary of BioTime, Inc., from November 2015 until November 2017, and Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine with clinical programs in spinal cord injury and oncology immunotherapy and a former subsidiary of BioTime, Inc., from March 2016 until November 2016. Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.
Richard S. Eiswirth

Richard S. Eiswirth,自2005年10月起,他担任公司首席财务官,自2010年8月担任首席营运官。从2003年至2005年 他担任创始品牌点火集团的合作伙伴,从事消费产品的收购活动。从2002年到2005 年他担任黑河控股公司(他于2002年成立的财务顾问公司)的总裁。他担任Netzee公司(为社区银行提供网上银行解决方案的供应商)的财务总监和高级执行副总裁从1999至2002年。1991至1999年,他在安达信担任了多种职位,在那里他开始了他的职业生涯。他曾任董事长琼斯纯碱公司(西雅图,华盛顿的饮料公司)的董事长,审核委员会主席及薪酬委员会成员各种职位有限公司,和彩色成像公司(一家格鲁吉亚的诺克罗斯的打印机和复印机原材料的生产商)的董事及审核委员会主席。 他曾是格鲁吉亚的执业会计师。 他持有维克森林大学的会计学士学位。


Richard S. Eiswirth,has served as Alimera Sciences, Inc. Chief Executive Officer and a member of the Board since January 2019. Mr. Eiswirth had previously served as Alimera Sciences, Inc. President and Chief Financial Officer since January 2016. Before that, he served as Alimera Sciences, Inc. Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as Alimera Sciences, Inc. Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks, from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chair, audit committee chair and member of the compensation committee of Jones Soda Co., a Seattle, Washington-based beverage company, and as director and audit committee chair of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a CPA in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.
Richard S. Eiswirth,自2005年10月起,他担任公司首席财务官,自2010年8月担任首席营运官。从2003年至2005年 他担任创始品牌点火集团的合作伙伴,从事消费产品的收购活动。从2002年到2005 年他担任黑河控股公司(他于2002年成立的财务顾问公司)的总裁。他担任Netzee公司(为社区银行提供网上银行解决方案的供应商)的财务总监和高级执行副总裁从1999至2002年。1991至1999年,他在安达信担任了多种职位,在那里他开始了他的职业生涯。他曾任董事长琼斯纯碱公司(西雅图,华盛顿的饮料公司)的董事长,审核委员会主席及薪酬委员会成员各种职位有限公司,和彩色成像公司(一家格鲁吉亚的诺克罗斯的打印机和复印机原材料的生产商)的董事及审核委员会主席。 他曾是格鲁吉亚的执业会计师。 他持有维克森林大学的会计学士学位。
Richard S. Eiswirth,has served as Alimera Sciences, Inc. Chief Executive Officer and a member of the Board since January 2019. Mr. Eiswirth had previously served as Alimera Sciences, Inc. President and Chief Financial Officer since January 2016. Before that, he served as Alimera Sciences, Inc. Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as Alimera Sciences, Inc. Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks, from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth serves as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chair, audit committee chair and member of the compensation committee of Jones Soda Co., a Seattle, Washington-based beverage company, and as director and audit committee chair of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a CPA in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.
David Holland

David Holland,他是公司的共同创办人之一,自公司于2003年成立到2010年8月他被任命为销售和市场营销的高级副总裁成立以来,他担任营销副总裁。在创办公司前,他担任诺华眼药的营销副总裁从1998至2003年。1997年他担任视康商务镜头的全球主管,1996年担任视康镜片清洁业务的全球主管。 1992至1995年他担任视康眼药水的营销总监。从1989至1991年他担任视康新产品经理。从1985至1989年他曾担任宝洁公司的品牌助理及助理品牌经理。他持有普林斯顿大学的政治学学士学位。


David Holland,is one of Alimera Sciences, Inc. co-founders and has served as Alimera Sciences, Inc. Chief Marketing Officer, Senior Vice President Corporate Communications and Managed Markets since January 2019. Prior to that, Mr. Holland served as the Vice President of Marketing from Alimera Sciences, Inc. inception in 2003 through August 2010, when he was appointed the Senior Vice President of Sales and Marketing, a position he held until January 2019. Prior to co-founding Alimera, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.
David Holland,他是公司的共同创办人之一,自公司于2003年成立到2010年8月他被任命为销售和市场营销的高级副总裁成立以来,他担任营销副总裁。在创办公司前,他担任诺华眼药的营销副总裁从1998至2003年。1997年他担任视康商务镜头的全球主管,1996年担任视康镜片清洁业务的全球主管。 1992至1995年他担任视康眼药水的营销总监。从1989至1991年他担任视康新产品经理。从1985至1989年他曾担任宝洁公司的品牌助理及助理品牌经理。他持有普林斯顿大学的政治学学士学位。
David Holland,is one of Alimera Sciences, Inc. co-founders and has served as Alimera Sciences, Inc. Chief Marketing Officer, Senior Vice President Corporate Communications and Managed Markets since January 2019. Prior to that, Mr. Holland served as the Vice President of Marketing from Alimera Sciences, Inc. inception in 2003 through August 2010, when he was appointed the Senior Vice President of Sales and Marketing, a position he held until January 2019. Prior to co-founding Alimera, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.
Philip Ashman

Philip Ashman,自2013年1月1日起他担任公司欧洲的高级副总裁和常务董事。在加入公司之前,他从2006年至2012年在拜耳担任了多个领导职务,负责拜耳英国市场准入战略的领导,涵盖了所有的治疗领域,包括眼科。在此之前,他担任拜耳全球营销肿瘤的副总裁兼,也是区域业务部-欧洲肿瘤科的副总裁,负责在欧洲,加拿大,中东及非洲肿瘤的销售和盈利目标的交付。在2006年之前他担任总部位于英国的阿斯利康和赛诺菲的业务领导职务。他拥有生物化学博士学位来自伦敦大学:英国的皇家霍洛威和贝德福德,和英国伦敦大学学院的生物化学学士学位。


Philip Ashman,has served as Chief Operating Officer and Senior Vice President Commercial Operations Europe since January 2019. Previously, Dr. Ashman served as the Senior Vice President, Managing Director Europe since January 2013. Prior to joining Alimera Sciences, Inc. , Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, including being responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.
Philip Ashman,自2013年1月1日起他担任公司欧洲的高级副总裁和常务董事。在加入公司之前,他从2006年至2012年在拜耳担任了多个领导职务,负责拜耳英国市场准入战略的领导,涵盖了所有的治疗领域,包括眼科。在此之前,他担任拜耳全球营销肿瘤的副总裁兼,也是区域业务部-欧洲肿瘤科的副总裁,负责在欧洲,加拿大,中东及非洲肿瘤的销售和盈利目标的交付。在2006年之前他担任总部位于英国的阿斯利康和赛诺菲的业务领导职务。他拥有生物化学博士学位来自伦敦大学:英国的皇家霍洛威和贝德福德,和英国伦敦大学学院的生物化学学士学位。
Philip Ashman,has served as Chief Operating Officer and Senior Vice President Commercial Operations Europe since January 2019. Previously, Dr. Ashman served as the Senior Vice President, Managing Director Europe since January 2013. Prior to joining Alimera Sciences, Inc. , Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, including being responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.